Sultopride
From Wikipedia, the free encyclopedia
 |
|
|---|---|
| Systematic (IUPAC) name | |
| N-[(1-ethylpyrrolidin-2-yl)methyl]-5-ethylsulfonyl-2-methoxy-benzamide | |
| Clinical data | |
| AHFS/Drugs.com | International Drug Names |
| Pregnancy cat. | ? |
| Legal status | ℞ Prescription only |
| Routes | Oral, IM |
| Pharmacokinetic data | |
| Half-life | 3-5 hours |
| Identifiers | |
| CAS number | 53583-79-2  |
| ATC code | N05AL02 |
| PubChem | CID 5357 |
| ChemSpider | 5164  |
| UNII | AA0G3TW31W |
| KEGG | D08549 |
| ChEMBL | CHEMBL277945 |
| Chemical data | |
| Formula | C17H26N2O4S |
| Mol. mass | 354.46 g/mol |
| SMILES | eMolecules & PubChem |
|
|
 (what is this?) (verify) |
Sultopride (Barnetil, Barnotil, Topral) is an atypical antipsychotic of the benzamide chemical class used in Europe, Japan, and Hong Kong for the treatment of schizophrenia.[1][2][3] It was launched by Sanofi-Aventis in 1976.[1] Sultopride acts as a selective D2 and D3 receptor antagonist.[4] It has also been shown to have clinically-relevant affinity for the GHB receptor as well, a property it shares in common with amisulpride and sulpiride.[5]
[edit] See also
[edit] References
- ^ a b José Miguel Vela; Helmut Buschmann; Jörg Holenz; Antonio Párraga; Antoni Torrens (2007). Antidepressants, Antipsychotics, Anxiolytics: From Chemistry and Pharmacology to Clinical Application. Weinheim: Wiley-VCH. ISBN 3-527-31058-4. http://books.google.com/books?id=yXD4QA-Y_Z0C&lpg=PA537&dq=sultopride&as_brr=3&pg=PA537#v=onepage&q=&f=false.
- ^ Swiss Pharmaceutical Society (2000). Index Nominum 2000: International Drug Directory (Book with CD-ROM). Boca Raton: Medpharm Scientific Publishers. ISBN 3-88763-075-0. http://books.google.com/books?id=5GpcTQD_L2oC&lpg=PA1624&dq=sultopride&as_brr=3&pg=PA983#v=onepage&q=&f=false.
- ^ European Drug Index, 4th Edition. Boca Raton: CRC Press. 1998. ISBN 3-7692-2114-1. http://books.google.com/books?id=HiSdvzs2pPAC&lpg=PA136&dq=sultopride&as_brr=3&pg=PA136#v=onepage&q=&f=false.
- ^ Burstein ES, Ma J, Wong S, et al. (December 2005). "Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist". The Journal of Pharmacology and Experimental Therapeutics 315 (3): 1278–87. doi:10.1124/jpet.105.092155. PMID 16135699. http://jpet.aspetjournals.org/cgi/pmidlookup?view=long&pmid=16135699.
- ^ Maitre M, Ratomponirina C, Gobaille S, Hodé Y, Hechler V (Apr 1994). "Displacement of [3H] gamma-hydroxybutyrate binding by benzamide neuroleptics and prochlorperazine but not by other antipsychotics". Eur J Pharmacol. 256 (2): 211–4. doi:10.1016/0014-2999(94)90248-8. PMID 7914168.
|
|
 |
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
